Early On-Treatment Ultrasound Tumor Shrinkage and HER2-Positive Residual Invasive Disease After Neoadjuvant Therapy: A 2-Center Study
Clinical Breast Cancer · 2026-11 · 26 (11) · 48-57
DOI: 10.1016/j.clbc.2026.09.006 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Breast Cancer, 2026-11. Verfasst von Chi Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing …. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Erb-b2 Receptor Tyrosine Kinases, Breast Neoplasms, Neoplasm, Residual. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chongqing Medical University, National Natural Science Foundation of China, Science-Health Joint Medical Scientific Research Project of Chongqing.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
- Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Electronic address: tiancx.cd@qq.com.
- Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. Electronic address: 37781380@qq.com.
- Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address: liushengchun…
Förderung
- Chongqing Medical University
- National Natural Science Foundation of China
- Science-Health Joint Medical Scientific Research Project of Chongqing
Zitieren
APA
Zhang, C., Zhou, L., Tang, L., Wang, Z., Li, S., Tang, Y., Tian, C., Liu, Z., & Liu, S. (2026). Early On-Treatment Ultrasound Tumor Shrinkage and HER2-Positive Residual Invasive Disease After Neoadjuvant Therapy: A 2-Center Study. Clinical Breast Cancer, 26(11), 48-57. https://doi.org/10.1016/j.clbc.2026.09.006
Vancouver
Zhang C, Zhou L, Tang L, Wang Z, Li S, Tang Y, et al. Early On-Treatment Ultrasound Tumor Shrinkage and HER2-Positive Residual Invasive Disease After Neoadjuvant Therapy: A 2-Center Study. Clinical Breast Cancer. 2026;26(11):48-57. doi:10.1016/j.clbc.2026.09.006
BibTeX
@article{Zhang2026,
author = {Zhang, Chi and Zhou, Lin and Tang, Lingfeng and Wang, Zijian and Li, Shunbo and Tang, Yimei and Tian, Chunxiang and Liu, Zeyu and Liu, Shengchun},
title = {Early On-Treatment Ultrasound Tumor Shrinkage and HER2-Positive Residual Invasive Disease After Neoadjuvant Therapy: A 2-Center Study},
journal = {Clinical Breast Cancer},
year = {2026},
volume = {26},
number = {11},
pages = {48--57},
doi = {10.1016/j.clbc.2026.09.006}
}
EUVIMED